Core Insights - Sol-Gel Technologies, Ltd. has entered into six exclusive license agreements for the commercialization of its dermatology products TWYNEO and EPSOLAY across multiple European countries, indicating strong market expansion potential [8][9] - The company is focused on developing innovative treatments for skin diseases, with TWYNEO approved for acne vulgaris and EPSOLAY approved for inflammatory lesions of rosacea [3][9] - Sol-Gel is conducting a Phase 3 clinical trial for SGT-610, a treatment for Gorlin syndrome, which is expected to enhance its competitive position in the dermatology market [8][10] Company Overview - Sol-Gel Technologies specializes in identifying, developing, and commercializing drug products for skin diseases, with a focus on innovative formulations [3][8] - The company has developed TWYNEO, a unique topical cream combining tretinoin and benzoyl peroxide, and EPSOLAY, which utilizes a patented technology for encapsulating benzoyl peroxide [2][9] - The company’s pipeline includes additional clinical trials for SGT-610 and SGT-210, targeting rare skin conditions and aiming for improved safety profiles [10] Market Expansion - The new license agreements cover major European markets including Germany, the UK, France, and others, reflecting a strategic move to enhance product availability [8][9] - Sol-Gel is set to receive upfront and regulatory milestone payments totaling up to low 7-digit USD, along with future royalties from net sales, backed by commitments to minimum annual sales [8][9] - The regulatory submissions in these territories will be managed by Sol-Gel's partners, with the company providing assistance in the preparation of these submissions [8]

Financial Performance - Sol-Gel Technologies Ltd. reported a quarterly loss of $0.23 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.15, representing an earnings surprise of -53.33% [1] - The company posted revenues of $0.47 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 64.15%, compared to year-ago revenues of $0.76 million [2] - The current consensus EPS estimate for the coming quarter is -$0.17 on $0.3 million in revenues, and for the current fiscal year, it is -$0.67 on $2.4 million in revenues [7] Stock Performance - Sol-Gel Technologies shares have declined approximately 32.1% since the beginning of the year, while the S&P 500 has gained 11.2% [3] - The company has surpassed consensus EPS estimates two times over the last four quarters, but has only topped consensus revenue estimates once in the same period [2] Industry Outlook - The Medical - Generic Drugs industry, to which Sol-Gel Technologies belongs, is currently in the top 25% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact the stock's performance [5]

Financial Results for the First Quarter Year Ended March 31st, 2024 NESS ZIONA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large- category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the first quarter ended March 31, 2024 and provided a ...

Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO® in China, Hong Kong, Macau, Taiwan and Israel, for a total consideration of up to $115 million. Sol-Gel recently initiated a proof-of-concept study for SGT-210 (topical erlotinib) in patients with Darier disease. Highly encouraging clinical response for SGT-210 from a Compassionate use treatment for a pediatric patient suf ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Exhibit 99.1 Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) - Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of SGT-610 (Patidegib gel, 2%), an Orphan Drug candidate with the potential to be the first therapy for preventing new basal cell carcinomas in Go ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report ________________ Commission file number 001-38367 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Sol-Gel NASDAQ: SLGL September 2020 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "future," "outlook," "intend," "target," "project," "contemplate," "believe," "estimate, ...